• Luis M Amezcua-Guerra, Luis F Pérez-García, Valentín Jiménez-Rojas, Ricardo Márquez-Velasco, and Luis H Silveira.
• Immunology Department, Instituto Nacional de Cardiología "Ignacio Chávez", Mexico City, Mexico.
• Gac Med Mex. 2023 Jan 1; 159 (1): 556455-64.

IntroductionAnti-Ro52/TRIM21 antibodies are markers for several systemic autoimmune rheumatic diseases (SARD).ObjectiveTo assess whether anti-Ro52/TRIM21 antibodies are related to abnormalities in inflammatory circuits.MethodsCross-sectional study of consecutive outpatients with SARD. Anti-Ro52/TRIM21 antibodies and serum amyloid A protein were measured by ELISA; panels for 18 cytokines and nine chemokines were analyzed on a Luminex reading platform, while high-sensitivity C-reactive protein (hs-CRP) and complement were measured by nephelometry.ResultsAmong 167 included patients, 143 had systemic lupus erythematosus (SLE), 16 had primary Sjögren's syndrome and eight had systemic sclerosis; 41 (24%) were positive for anti-Ro52/TRIM21 antibodies. Patients with anti-Ro52/TRIM21 antibodies had higher serum levels of IL-2, IL-4, IL-6, GM-CSF, IL-21, IL-22, hs-CRP and chemokines CCL4, CXCL8, CXCL10 and CXCL12, but lower levels of complement C4. Anti-Ro52/TRIM21 antibody titers were positively correlated with IL-2, IL-4, IL-6, IL-10, IL-21, IL-22, CXCL10, and hs-CRP, and negatively with complements C3 and C4. When only SLE patients were included, no association was identified between anti-Ro52/TRIM21 antibodies and disease activity or organ-specific involvement.ConclusionsAnti-Ro52/TRIM21 antibodies are associated with aberrant cytokine circuits and elevated levels of angiogenic molecules and neutrophil and monocyte chemoattractants, which suggests an active role for these antibodies in SARD.Copyright: © 2023 Permanyer.

18 keywords...

hide…